CytoMed Therapeutics Ltd. has issued a statement refuting recent inaccurate and misleading claims about its research programs, clinical progress, and operations. The company clarified that its scientific focus, development status, and regulatory standing have been mischaracterized by certain public statements. CytoMed emphasized that its lead CAR γδ T cell therapy has regulatory approval for a first-in-human clinical trial currently underway at National University Hospital in Singapore, conducted under appropriate regulatory and ethical guidelines. The company also noted that other programs, such as iPSC-derived γδ NKT cell therapies, remain in preclinical development and are not approved for commercial use. CytoMed reaffirmed its commitment to accurate communication and compliance with applicable regulations, and reserved the right to address the spread of false or misleading information.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cytomed Therapeutics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9644463-en) on January 28, 2026, and is solely responsible for the information contained therein.